A retrospective cohort study examined the risk of developing colorectal cancer in over 1.2 million patients with T2DM who were prescribed GLP-1RAs, insulin, metformin and other oral anti-diabetic medications between 2005 and 2019. Here, INS is linked to type 2 diabetes mellitus.